Ipamorelin Research Peptide

Peptora Compound Research Library

Ipamorelin Research Peptide Overview

Ipamorelin Research Peptide literature examines a synthetic pentapeptide growth-hormone secretagogue studied through the ghrelin/GHS-R1a receptor pathway. Experimental research has investigated its peptide structure, receptor signalling, selective growth-hormone release, pharmacokinetics and gastrointestinal-motility models.

Research Library Commonly Studied Peptides Testing & COAs Research Peptides

Compound overview

What Is Ipamorelin Research Peptide?

Ipamorelin is a synthetic pentapeptide originally developed and characterized as a selective growth-hormone secretagogue.

Its reported sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH₂. This structure includes non-standard and D-amino-acid components and differs substantially from endogenous ghrelin.

Despite those structural differences, ipamorelin acts through the growth-hormone-secretagogue receptor pathway. Contemporary literature commonly identifies this receptor as GHS-R1a, the ghrelin receptor.

Ipamorelin at a Glance

Peptide class: synthetic pentapeptide growth-hormone secretagogue.

Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂.

Primary research target: ghrelin/growth-hormone-secretagogue receptor, GHS-R1a.

Major research themes: GH release, receptor selectivity, pharmacokinetics and gastrointestinal motility.

Peptide structure

Ipamorelin Research Peptide Structure

Ipamorelin contains five residues and was identified during structure-activity research involving earlier growth-hormone-releasing peptides.

Pentapeptide

Ipamorelin is composed of five residues, making it considerably shorter than many naturally occurring peptide hormones.

Aib

Aib Residue

The N-terminal residue is α-aminoisobutyric acid, commonly abbreviated Aib.

D-Amino-Acid Components

The structure includes D-2-naphthylalanine and D-phenylalanine rather than only naturally occurring L-amino acids.

These structural features help illustrate why peptide identity cannot be established merely from a compound name. Analytical documentation remains important when evaluating a specific laboratory research batch.

Receptor biology

Ipamorelin and the Ghrelin/GHS-R1a Receptor

The growth-hormone secretagogue receptor was characterized through research involving synthetic GH-releasing compounds and was subsequently identified as the receptor for the endogenous peptide ghrelin.

Ipamorelin functions as an agonist within this receptor system. Activation of GHS-R1a can influence signalling involved in pituitary growth-hormone release and other physiological pathways associated with ghrelin-receptor biology.

GHS-R1a

The ghrelin receptor provides the primary receptor framework used to interpret ipamorelin pharmacology.

Pituitary Signalling

Experimental receptor activation is associated with stimulation of growth-hormone release from the pituitary.

Ghrelin-Mimetic Research

Ipamorelin is frequently described as a ghrelin mimetic because it activates the ghrelin-receptor pathway without sharing ghrelin's full peptide structure.

Receptor Distribution

GHS-R1a biology extends beyond the pituitary, contributing to research involving gastrointestinal and other physiological systems.

Selectivity research

Why Ipamorelin Is Described as a Selective GH Secretagogue

The original pharmacological characterization compared ipamorelin with earlier secretagogues including GHRP-2 and GHRP-6.

In experimental swine, the investigators reported GH release without significant increases in ACTH or cortisol beyond levels observed with GHRH stimulation. By contrast, GHRP-2 and GHRP-6 increased ACTH and cortisol in that model.

The researchers therefore described ipamorelin as a GHRP-receptor agonist with comparatively strong selectivity for GH release.

Evidence context: “selective” describes the endocrine profile observed under specific experimental conditions. It does not mean the compound acts exclusively on one biological process or establishes a particular safety profile in humans.

Human research

Ipamorelin Research Peptide Pharmacokinetics

Ipamorelin has also been investigated in human pharmacokinetic and pharmacodynamic research.

A 1999 study enrolled healthy male volunteers across five intravenous infusion levels. Under those study conditions, pharmacokinetic measurements were dose-proportional and the reported terminal half-life was approximately two hours.

The investigators observed an episodic GH response, with peak GH occurring approximately 0.67 hours after the infusion and declining thereafter.

How to Interpret the Human PK Study

The study provides controlled pharmacokinetic and pharmacodynamic information about ipamorelin under the specific intravenous research protocol used by the investigators.

It should not be converted into dosing or administration guidance, and its pharmacokinetic measurements should not automatically be assumed to apply to different experimental conditions or routes.

GH signalling

Ipamorelin and Growth-Hormone Release Research

Growth-hormone release is the central pharmacodynamic endpoint throughout much of the ipamorelin literature.

The original 1998 study demonstrated GH-releasing activity in primary rat pituitary cells, anesthetized rats and conscious swine. Human volunteer research subsequently documented a measurable GH response as well.

Research Model	Research Focus	Interpretation
Rat pituitary cells	Direct GH release in vitro	Cellular evidence of secretagogue activity
Rat models	GH release and biological responses	Preclinical whole-animal evidence
Swine	GH release and endocrine selectivity	Preclinical endocrine profiling
Healthy volunteers	Pharmacokinetics and GH response	Controlled human PK/PD evidence under defined study conditions

Gastrointestinal research

Ipamorelin and Ghrelin-Receptor Motility Research

Because ghrelin-receptor signalling is also associated with gastrointestinal function, ipamorelin has been investigated outside the growth-hormone research setting.

In a rodent model of postoperative ileus, investigators reported that ipamorelin accelerated gastrointestinal transit and improved selected experimental measures following intestinal manipulation. :contentReference[oaicite:2]{index=2}

A subsequent randomized proof-of-concept study investigated ipamorelin in 117 patients undergoing bowel resection. The primary endpoint—time to tolerance of a standardized solid meal—was not significantly different between the ipamorelin and placebo groups. :contentReference[oaicite:3]{index=3}

Why negative or neutral findings matter: responsible research summaries should include results that do not demonstrate the proposed clinical effect. The human postoperative-ileus trial did not establish significant efficacy for its primary endpoint.

Related compounds

Ipamorelin vs CJC-1295 No DAC Research

Ipamorelin and CJC-1295 No DAC are often discussed together, but they interact with different receptor systems.

Ipamorelin is studied primarily through the ghrelin/GHS-R1a receptor. CJC-1295 No DAC / Modified GRF (1-29) is studied through the GHRH receptor.

Feature	Ipamorelin	CJC-1295 No DAC
Peptide type	Synthetic pentapeptide secretagogue	Modified 29-residue GHRH-related analogue
Primary receptor framework	Ghrelin / GHS-R1a receptor	GHRH receptor
Research pathway	Growth-hormone secretagogue signalling	Growth hormone-releasing hormone signalling
Evidence requirement	Evaluate ipamorelin evidence independently	Evaluate Modified GRF evidence independently

For the complementary receptor pathway, see our CJC-1295 No DAC Research Peptide Overview.

Research principle: a theoretical rationale for studying two compounds together is not equivalent to controlled evidence demonstrating that the combination produces a particular outcome.

Combination research

CJC-1295 No DAC + Ipamorelin Research Context

The two compounds are frequently paired in research-material discussions because they approach the GH axis through different receptor pathways.

That distinction provides a mechanistic reason researchers may be interested in studying the compounds in the same experimental framework. However, evidence supporting each individual peptide should remain separate from evidence specifically examining a combination.

Peptora's current research catalogue includes a CJC-1295 No DAC + Ipamorelin research material. The composition of a combined research material does not establish synergistic biological effects; those require direct experimental evidence.

Evidence interpretation

Understanding Ipamorelin Research Evidence

The ipamorelin literature includes cellular, animal and human investigations, but the significance of each evidence type differs.

✓ Cell assays demonstrate mechanistic activity.

✓ Animal endocrine findings remain preclinical.

✓ Human PK studies describe defined study conditions.

✓ GH release is not itself a clinical outcome.

✓ Receptor activity does not establish therapeutic efficacy.

✓ Combination claims require combination-specific evidence.

Analytical documentation

Ipamorelin Research Peptide: Purity, Identity and Batch Testing

Published pharmacology does not establish the composition, purity or measured content of a particular supplied batch.

Researchers should evaluate batch-specific analytical documentation independently from the broader scientific literature.

✓ Confirm the stated material identity.

✓ Match documentation to the applicable batch.

✓ Review purity where reported.

✓ Review identity testing where reported.

✓ Review measured content where reported.

✓ Identify the analytical methods used.

✓ Review additional testing only where documented.

✓ Never transfer one batch's results to another.

For the broader analytical framework, read Peptide Purity & Certificates of Analysis (COAs) Explained and Peptora's Testing & COAs.

Research network

Continue Exploring Ipamorelin and Related Research

This overview connects ipamorelin with Peptora's broader educational network covering GH-related research peptides, peptide stability, analytical documentation and compound-specific research.

Related Peptide Research Resources

Continue into related compound overviews and foundational research education.

CJC-1295 No DAC Research Peptide Overview → Tesamorelin Research Peptide Overview → Sermorelin Research Peptide Overview → Commonly Studied Research Peptides in Canada → What Are Research Peptides? → Understanding Peptide Stability → Peptide Purity & COAs Explained → Complete Research Library →

Ipamorelin FAQ

Ipamorelin Research Peptide: Frequently Asked Questions

Common research questions about ipamorelin structure, GHS-R1a signalling, growth-hormone release and related peptide research.

What is the Ipamorelin research peptide?

Ipamorelin is a synthetic pentapeptide growth-hormone secretagogue investigated through the ghrelin/GHS-R1a receptor pathway.

What is the structure of ipamorelin?

The reported peptide sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH₂. It contains five residues and includes non-standard and D-amino-acid components.

What receptor does ipamorelin activate?

Ipamorelin is studied as an agonist of the growth-hormone-secretagogue receptor GHS-R1a, commonly known as the ghrelin receptor.

Why is ipamorelin called a selective growth-hormone secretagogue?

Early pharmacological research found strong GH-releasing activity while showing comparatively limited ACTH and cortisol responses in the experimental models used, distinguishing it from some earlier secretagogues.

Has ipamorelin been studied in humans?

Yes. Controlled human research has examined ipamorelin pharmacokinetics and growth-hormone responses in healthy volunteers, and it was also investigated in a clinical postoperative-ileus study.

Is ipamorelin the same as CJC-1295 No DAC?

No. Ipamorelin is a ghrelin/GHS-R1a receptor agonist, while CJC-1295 No DAC, commonly associated with Modified GRF (1-29), is studied through the GHRH receptor.

Does combining ipamorelin with CJC-1295 prove synergy?

No. Different receptor pathways can provide a mechanistic reason to study compounds together, but synergy or a specific combined outcome requires direct evidence involving the combination.

Does published ipamorelin research verify a specific research batch?

No. Published research describes defined experimental materials. A specific laboratory batch must be evaluated using the analytical documentation associated with that batch.

Research use only

Ipamorelin Research Peptide for Controlled Laboratory Research

This overview provides educational information about ipamorelin and areas investigated in published scientific literature. Findings involving receptor assays, animal experiments, human pharmacokinetic research or gastrointestinal models should be interpreted according to the design and limitations of the applicable study.

Peptora Peptide Labs research products are intended solely for controlled non-clinical laboratory research. They are not intended for human or veterinary consumption, compounding or clinical use. Nothing on this page provides medical advice, dosing or administration guidance, or representations concerning diagnosis, treatment, cure or prevention of disease.